Presented by

NEWS
A Little Prick Goes A Long Way: HIMS’ Big Gain 💪

The Fed minutes showed the big-wigs are keeping a wary eye on inflation and Trump’s tariff threats, leaving traders guessing on the next move. Barrick Gold is handing Mali $438 million to settle a two-year mining dispute just as gold prices hit record highs. And over in Cupertino, Apple dropped the iPhone 16e with its first in-house modem and AI perks, but nobody cared. 👀 

Today's issue covers HIMS & HERS pumping up its offering, retail favorites like Carvana reporting results, and other earnings pops & drops from the day. 📰

Here’s the S&P 500 heatmap. 9 of 11 sectors closed green, with healthcare (+1.30%) leading and materials (-1.18%) lagging.

And here are the closing prices: 

COMPANY NEWS
No More Half Measures: HIMS & HERS Promises Bigger, Stronger Results 💪 

Hims & Hers just went full throttle on your personal well-being by snatching up an at-home lab testing facility (Sigmund NJ LLC, a.k.a. Trybe Labs). They want to keep you at peak performance so you can flex your health stats with confidence. 🫡 

A quick prick of the finger, and you’ll know if your hormone levels are standing at attention or losing steam. It’s all about delivering the goods on everything from cholesterol and liver function to testosterone, thyroid, and cardiac risk.

While some investors were immediate believers, skeptics were quick to point out that what is being described sounds a lot like what the infamous Elizabeth Holmes of Theranos tried selling not too long ago.

HIMS considers this acquisition a hard push toward a future where your health data works for you. No half measures, no limp strategies. Just straightforward access to personalized care so you can stay in control. 💊 

HIMS closed with a +17% gain and another new all-time high. It’s up +180% since the beginning of the year. But what happens after today’s big move? Here’s what Stocktwits users said:

It appears everyone’s eye is on the sky. At least while the momentum continues... 👀 

SPONSORED
PE Funding Secured: $100MM+ Dermatology Disrupter Opportunity Closing Soon

🧪 Survivor to founder… Facing an infection with a 70% fatality rate and no available cure, Bradley Burnam decided to develop one himself and Turn Therapeutics was born. The $123M company is on a mission to deliver unparalleled advancements in advanced wound care, eczema, and onychomycosis– a combined $25B+ market. 

🤝 Backed and funded… With already $15M+ in total funding, the company built on the back of Burnam’s cure received a commitment from PE group, GEM, to purchase up to $75 million of stock upon a public listing.

🚀 NASDAQ ticker secured…Turn Therapeutics was granted its Nasdaq ticker, TTRX. The company is inviting all investors to join its crowdfunding campaign on StartEngine: a unique opportunity to be an early investor in a biotech company that has the potential to revolutionize healing.

⏰ Closing soon… This campaign will be ending in less than 30 days, so don’t miss your opportunity and invest today!

*3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here.